GlassScriptPhysician profile
Brian G Martin
NPI 1235197211
$10,756.21
in general payments reported to CMS, 2019-2025
37 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $884 · 2021: $2,000 · 2022: $2,064 · 2023: $1,805 · 2024: $1,495 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,437.14 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,085.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,081.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,057.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $650.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $591.90 | 2019-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $563.18 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $555.50 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $543.68 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $539.15 | 2023-2025 | Gemtesa, Myfembree |
| Abbott Laboratories | $526.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $422.95 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.14 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $407.88 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $354.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $308.71 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.